- Home
- ELVN
as 05-30-2025 11:35am EST
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | BOULDER |
| Market Cap: | 927.8M | IPO Year: | 2020 |
| Target Price: | $37.25 | AVG Volume (30 days): | 357.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.93 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.30 - $30.03 | Next Earning Date: | 05-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Enliven Therapeutics Inc. (ELVN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hohl Benjamin | ELVN | CHIEF FINANCIAL OFFICER | May 27 '25 | Sell | $16.18 | 3,250 | $52,593.45 | 23,000 | |
| Lyssikatos Joseph P | ELVN | CHIEF SCIENTIFIC OFFICER | May 19 '25 | Sell | $16.31 | 5,000 | $81,533.50 | 985,188 | |
| Kintz Samuel | ELVN | PRESIDENT AND CEO | May 19 '25 | Sell | $16.49 | 5,000 | $82,453.00 | 972,892 | |
| Patel Anish | ELVN | CHIEF OPERATING OFFICER | May 7 '25 | Sell | $19.19 | 6,667 | $122,578.86 | 310,080 | |
| Lyssikatos Joseph P | ELVN | CHIEF SCIENTIFIC OFFICER | May 1 '25 | Sell | $20.04 | 7,500 | $150,390.64 | 985,188 | |
| Kintz Samuel | ELVN | PRESIDENT AND CEO | May 1 '25 | Sell | $20.04 | 7,500 | $150,415.36 | 972,892 | |
| Hohl Benjamin | ELVN | CHIEF FINANCIAL OFFICER | Apr 28 '25 | Sell | $18.90 | 3,250 | $60,737.55 | 23,000 | |
| Lyssikatos Joseph P | ELVN | CHIEF SCIENTIFIC OFFICER | Apr 21 '25 | Sell | $16.37 | 5,000 | $80,365.82 | 985,188 | |
| Kintz Samuel | ELVN | PRESIDENT AND CEO | Apr 17 '25 | Sell | $16.42 | 5,000 | $82,096.00 | 972,892 | |
| Patel Anish | ELVN | CHIEF OPERATING OFFICER | Apr 7 '25 | Sell | $18.46 | 6,667 | $120,268.73 | 310,080 |
Latest Enliven Therapeutics Inc. News
ELVN Breaking Stock News: Dive into ELVN Ticker-Specific Updates for Smart Investing
MT Newswires
5 hours ago
Mizuho Adjusts Price Target on Enliven Therapeutics to $41 From $39, Maintains Outperform Rating
PR Newswire
8 days ago
Enliven Therapeutics to Present at Upcoming Investor Conferences
TipRanks
13 days ago
Enliven price target lowered to $27 from $36 at JonesResearch
PR Newswire
16 days ago
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
PR Newswire
16 days ago
Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress
PR Newswire
2 months ago
Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting
PR Newswire
3 months ago
Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
PR Newswire
3 months ago
Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
Compare ELVN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ELVN Enliven Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.